Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: A potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial

European Journal of Heart Failure

Volumn 13, Issue 12, 2011, Pages 1261-1263

  Pitt, Bertram ^a   Gheorghiade, Mihai ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DIURETIC AGENT; EPLERENONE; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; SPIRONOLACTONE; TOLVAPTAN; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

BODY WEIGHT; DRUG MEGADOSE; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOCONCENTRATION; LUNG CONGESTION; PERIPHERAL EDEMA; PLASMA VOLUME; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

ALDOSTERONE; BENZAZEPINES; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASOPRESSIN; TREATMENT FAILURE;

EID: 81855194762     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr150     Document Type: Editorial

References (29)

1. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010;12:423-433.
2. Ling H, Aung N, Flint J, Aggarwal S, Cheng A, Thomas M, Woldman S, Okonko D. Calculated plasma volume status and mortality in chronic heart failure. J Am Coll Cardiol 2011;57:pE370.
3. McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004;44:1301-1307. (Pubitemid 39208889)
4. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-708. (Pubitemid 37000189)
5. Hasselblad V, Gattis StoughW, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-1069. (Pubitemid 47451811)
6. Lee CR, Watkins ML, Patterson JH, Gattis W, O'Connor CM, Gheorghiade M, Adams KF Jr. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146:9-18. (Pubitemid 36851295)
7. Udelson JE, McGrew F, Flores E, al. E. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007;49:2151-2159. (Pubitemid 46817812)
8. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297:1319-1331. (Pubitemid 46513233)
9. Zmily HD, Daifallah S, Ghali JK. Tolvaptan, hyponatremia, and heart failure. Int J Nephrol Renovasc Dis 2011;4:57-71.
10. Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr., Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghiade M. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J 2009;30: 1666-1673.
11. Konstam MA, Udelson JE. Hyponatraemia and vasopressin in heart failure: markers or mediators? Eur J Heart Fail 2011;13:242-244.
12. Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, Miyazaki H, Fujiwara Y, Nakayama Y, Kohda Y, Yamauchi J, Inoue T, Kawahara K, Saito H, Tomita K, Nonoguchi H, Tanoue A. Vasopressin regulates the renin-angiotensin- aldosterone system via v1a receptors in macula densa cells. Am J Physiol Renal Physiol 2008;295:F100-F107.
13. Izumi Y, Hori K, Nakayama Y, Kimura M, Hasuike Y, Nanami M, Kohda Y, Otaki Y, Kuragano T, Obinata M, Kawahara K, Tanoue A, Tomita K, Nakanishi T, Nonoguchi H. Aldosterone requires vasopressin v1a receptors on intercalated cells to mediate acid-base homeostasis. J Am Soc Nephrol 2011;22:673-680.
14. Tashima Y, Kohda Y, Nonoguchi H, Ikebe M, Machida K, Star RA, Tomita K. Intranephron localization and regulation of the v1a vasopressin receptor during chronic metabolic acidosis and dehydration in rats. Pflugers Arch 2001;442: 652-661. (Pubitemid 32783673)
15. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M. Acute hemodynamic effects of tolvaptan, a vasopressin v2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52: 1540-1545.
16. Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y. Effects of v2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol 2008;75:1322-1330.
17. Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev 2011;in press.
18. Yoshida M, Ma J, Tomita T, Morikawa N, Tanaka N, Masamura K, Kawai Y, Miyamori I. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 2005;11:12-16.
19. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN, Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010; 120:3350-3364.
20. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007;115:1754-1761. (Pubitemid 46648612)
21. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007;13:189-197.
22. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 2002;970:89-100. (Pubitemid 35286086)
23. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006;47: 312-318. (Pubitemid 43740260)
24. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000;58:1219-1227
25. Pitt B. Plasma aldosterone levels in patients with coronary artery disease without heart failure or myocardial infarction: implications for pathophysiology, prognosis, and therapy. Eur Heart J 2011;in press.
26. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
27. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-717. (Pubitemid 29407370)
28. van Vliet A, Donker A, Nauta J, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:21A-28A.
29. Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JC Jr. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ Heart Fail 2010;3:412-419.